Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naproxcinod in Osteoarthritis of the Hip
NCT00541489Phase 3Completed
- Sponsor
- Nicox S.A.
- Start
- Jun 2007
- Primary completion
- Sep 2008
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of naproxcinod in osteoarthritis (OA) (3 arms), sponsored by Nicox S.A. Primary endpoints: Western Ontario and McMaster Universities Osteoarthritis Index Pain Subscale at 13 weeks, Western Ontario and McMaster Universities Osteoarthritis Index Function Subscale at 13 weeks and 1 more. Started Jun 2007; status: completed.
02
Drugs
naproxcinod
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT00541489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00541489.